Applied DNA Schedules Fourth Quarter and Full Fiscal Year 2021 Financial Results Conference Call and Webcast for Thursday, December 9, 2021
December 03 2021 - 10:00AM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the
“Company”), a leader in Polymerase Chain Reaction (PCR)- based DNA
manufacturing and nucleic acid-based technologies, today announced
that it will report its fourth quarter and full fiscal year 2021
financial results after market close on Thursday, December 9, 2021.
The Company’s management will discuss the results during a
conference call and simultaneous webcast at 4:30 p.m. ET that same
day. Presentation slides will also be posted to the ‘Company
Events’ sub-page of the Company’s Investor Relations website and
embedded into the live webcast.
Conference Call
and Webcast Information - Live
Date:
Thursday, December 9, 2021, at 4:30 p.m.
Eastern Time
Dial in:
844-887-9402
412-317-6798 (international)
Hosts:
Dr. James A. Hayward, chairman, president,
and CEO
Beth Jantzen, chief financial officer
Webcast:
https://services.choruscall.com/mediaframe/webcast.html?webcastid=kEXAzeGn
Conference Call
and Webcast Information - Replay
A telephonic replay of the conference call
will be available for one week beginning one hour after the end of
the live conference call.
Dial in:
877-344-7529
412-317-0088 (international)
Access Code: 10161912
Webcast:
https://services.choruscall.com/mediaframe/webcast.html?webcastid=kEXAzeGn
Availability:
Telephonic replay: until December 16,
2021; webcast replay: 1 year
About Applied DNA Sciences
Applied DNA is commercializing LinearDNA™, its proprietary,
large-scale polymerase chain reaction (“PCR”)-based manufacturing
platform that allows for the large-scale production of specific DNA
sequences.
The LinearDNA platform has utility in the nucleic acid-based in
vitro diagnostics and preclinical nucleic acid-based drug
development and manufacturing market. The platform is used to
manufacture DNA for customers as components of in vitro diagnostic
tests and for preclinical nucleic acid-based drug development in
the fields of adoptive cell therapies (CAR T and TCR therapies),
DNA vaccines (anti-viral and cancer), RNA therapies, clustered
regularly interspaced short palindromic repeats (CRISPR) based
therapies, and gene therapies.
The LinearDNA platform also has non-biologic applications, such
as supply chain security, anti-counterfeiting and anti-theft
technology. Key end-markets include textiles, pharmaceuticals and
nutraceuticals, and cannabis, among others.
Leveraging its deep expertise in nucleic acid-based
technologies, the Company has also established safeCircle™, a
pooled COVID-19 testing program that is grounded in the Company’s
EUA-authorized Linea™ COVID-19 Assay Kit. safeCircle is designed to
look for infection within defined populations or communities
utilizing pooled testing methodologies that increase testing
efficiencies. The Company has also developed and plans to seek
EUA-authorization for its LineaTM SARS-CoV-2 Mutation Panel, an
assay-based panel for the detection of certain SARS-CoV-2 genetic
mutations.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker
symbol ‘APDN,’ and its publicly traded warrants are listed on OTC
under ticker symbol ‘APPDW.’
Applied DNA is a member of the Russell Microcap® Index.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211203005320/en/
Investor Relations: Sanjay M. Hurry, 917-733-5573,
sanjay.hurry@adnas.com Web: www.adnas.com Twitter:
@APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024